Bone marrow-derived mesenchymal stem cells mitigate colistin-induced cochlear ototoxicity: an experimental study
Öz
Purpose: This study investigates the therapeutic potential of mesenchymal stem cells in colistin-induced hearing loss.
Materials and Methods: Forty Wistar albino rats were divided into four groups (n=10): Control (36 mg/kg/day intraperitoneal (ip) saline for 7 days), Colistin (36 mg/kg/day ip for 7 days), Mesenchymal stem cell group (MSC) (5×10⁶ MSC via tail vein), and Colistin+Mesenchymal stem cell group (Col+MSC) (colistin for 7 days, then MSC 1 hour after final dose). After the experiment, cochlear tissues were extracted, fixed, decalcified, embedded in paraffin, sectioned (5µm), and stained with Masson’s trichrome (MT) for histological evaluation under light microscopy.
Results: Colistin caused marked structural damage, especially in the basal and medial cochlear turns. In the apical and medial regions, stria vascularis thickness was significantly lower in the colistin group (10.64±1.90, 11.54±2.32) than in the control (14.12±2.03, 15.43±2.26) and MSC (13.91±1.49, 14.53±1.80) groups. Significant intergroup differences were also noted in the basal turn. Inner hair cell lengths were similar apically but significantly reduced in the colistin (30.73±4.28) and Col+MSC (31.06±6.96) groups medially. Outer hair cell lengths were significantly reduced in the colistin group in both apical (32.23±8.32) and basal (18.32±2.47) regions. Tectorial membrane thickness in the basal turn was significantly reduced in all treatment groups compared to the control (17.64±5.41). Based on Freitas et al.'s criteria, the colistin group showed significantly higher histopathological damage scores in all regions compared to the control and MSC groups. The Col+MSC group showed improved morphology and lower scores, though some differences lacked statistical significance.
Conclusion: MSCs significantly alleviated colistin-induced ototoxicity, indicating their protective and therapeutic potential in inner ear injury.
Anahtar Kelimeler
Colistin;, ototoxicity,, mesenchymal stem cell,, cochlea,, organ of corti
Destekleyen Kurum
Erciyes Üniversitesi Bilimsel Araştırma Projeleri bu çalışmayı finanse etti.
Proje Numarası
TSA-2021-11331
Etik Beyan
Number 24/234- Approval date 05/12/2024
Kaynakça
- Park YH. Stem cell therapy for sensorineural hearing loss, still alive? J Audiol Otol. 2015;19:63-7.
- Kwa A, Kasiakou SK, Tam VH, Falagas ME. Polymyxin B: similarities to and differences from colistin (polymyxin E). Expert Rev Anti Infect Ther. 2007;5:811-21.
- Leong KW, Ong S, Chee HL, Lee W, Kwa AL. Hypersensitivity pneumonitis due to high-dose colistin aerosol therapy. Int J Infect Dis. 2010;14:e1018-9.
- Levin AS, Barone AA, Penço J, Santos MV, Marinho IS, Arruda EA et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis. 1999;28:1008-11.
- Li J, Turnidge J, Milne R, Nation RL, Coulthard K. In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother. 2001;45:781-5.
- Markantonis SL, Markou N, Fousteri M, Sakellaridis N, Karatzas S, Alamanos I et al. Penetration of colistin into cerebrospinal fluid. Antimicrob Agents Chemother. 2009;53:4907-10.
- Bergen PJ, Landersdorfer CB, Zhang J, Zhao M, Lee HJ, Nation RL et al. Pharmacokinetics and pharmacodynamics of 'old' polymyxins: what is new? Diagn Microbiol Infect Dis. 2012;74:213-23.
- Giamarellou H. Multidrug-resistant Gram-negative bacteria: how to treat and for how long. Int J Antimicrob Agents. 2010;36:S50-4.
- Lim LM, Ly N, Anderson D, Yang JC, Macander L, Jarkowski A 3rd et al. Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing. Pharmacotherapy. 2010;30:1279-91.
- Boisson M, Gregoire N, Couet W, Mimoz O. Colistin in critically ill patients. Minerva Anestesiol. 2013;79:200-8.
